TY - JOUR
T1 - Combining molecularly targeted agents
T2 - Is more always better?
AU - Sundar, Raghav
AU - Valeri, Nicola
AU - Harrington, Kevin J.
AU - Yap, Timothy A.
N1 - Publisher Copyright:
©2016 AACR.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials.
AB - The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials.
UR - http://www.scopus.com/inward/record.url?scp=85014567432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014567432&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-2399
DO - 10.1158/1078-0432.CCR-16-2399
M3 - Article
C2 - 27836864
AN - SCOPUS:85014567432
SN - 1078-0432
VL - 23
SP - 1123
EP - 1125
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 5
ER -